100%
Skip to main content
Platform
GovTribe AI
AI-powered insights to accelerate your government contracting workflow.
MCP Server
Connect GovTribe to your AI tools.
Beacon
Find and connect with key government decision-makers.
Profiles
Federal Agencies
Federal Contract Vehicles
Federal Grant Programs
Major Defense Acquisition Programs
NAICS Categories
PSC Categories
States
Jurisdictions
NIGP Categories
UNSPSC Categories
Vendors
Enrichment By Clearbit
Reports
New Entrants
Funding Analysis
Vehicle Analysis
Groups
Capture
Pipelines
Pursuits
Alerts
Teaming
Data
Awards
Forecasts
Federal Opportunities
State & Local Opportunities
Files
Prime and Subcontractors
Activity
Search
Exports
Solutions
Use Case
Opportunity Identification
Capture Management
Competitive Intelligence
Teaming & Partner Identification
Proposal Management
Strategic Leadership
Go-to-Market Strategy
Industry
Federal Contractors
State & Local Contractors
Grant Seekers
Government Agencies
Research & Consulting
Pricing
More
About Us
Features
Get A Demo
Sign Up
Blog
User Guide
Data Model
GovTribe for Agents
Login
Contact sales
Try for free
Login
Contact sales
Try for free
All Federal Grant Awards
Project Grant R43OD028233
Award Date
9/6/19
Completion Date
9/5/23
Dollars Obligated
$225K
Overview
Activity
7
Transactions
7
Subawards
Similar Awards
Funding Federal Agency
Office of the Director
Awarding Federal Agency
Aggregate Financial Assistance Data
Awardee
Microtek (L77AH9NS6Y45)
Federal Grant Program
93.351
Assistance Type
Project Grant
Place of Performance
California, USA
Update #1
Update #2
DEVELOPMENT OF AN INTRATRACHEAL DEVICE TO AUTOMATE AIRWAY DRUG DELIVERY IN ANIMAL MODELS
Posted 9/5/19
5
1
2
Mod #
Description
ReasonForModification
Federal Obligation
Date
Not listed
DEVELOPMENT OF AN INTRATRACHEAL DEVICE TO AUTOMATE AIRWAY DRUG DELIVERY IN ANIMAL MODELS - PROJECT SUMMARY / ABSTRACT THE RATE OF FDA APPROVAL FOR RESPIRATORY DRUGS IS ONLY 3%, MUCH LOWER THAN DRUGS DEVELOPED FOR OTHER KEY THERAPEUTIC AREAS. THE LOWER SUCCESS RATE FOR RESPIRATORY DRUGS CAN BE ATTRIBUTED TO THE LACK OF INNOVATION FOR DEVELOPING INHALED THERAPEUTICS, ESPECIALLY TOOLS NEEDED FOR EARLY DRUG DEVELOPMENT PHASES. THE EARLY ASSESSMENT OF A DRUG'S METABOLISM, PHARMACOKINETICS, AND TOXICOLOGY (DMPK/TOX) ARE EXTREMELY CRITICAL. PRECLINICAL ANIMAL STUDIES REDUCE THE TIME AND COSTS EXPENDED WITH THE DEVELOPMENT OF NEW DRUGS, THUS INCREASING THE OVERALL SUCCESS OF BRINGING NEW THERAPIES TO MARKET. HOWEVER, FOR ANIMAL MODELS OF LUNG DISEASES, CURRENT METHODS FOR AIRWAY DOSING HAVE MAJOR LIMITATIONS THAT GREATLY AFFECT THE DATA QUALITY, RELIABILITY AND FEASIBILITY OF DMPK/TOX STUDIES. TO ADDRESS THESE LIMITATIONS, OUR PROPOSED PROJECT WILL DEVELOP A NEW TOOL FOR USE DURING THE PRECLINICAL STAGES OF DRUG DEVELOPMENT OF INHALED THERAPEUTICS. WE WILL DESIGN AND ASSEMBLE A WORKING PROTOTYPE OF A MINIATURIZED INTRATRACHEAL DEVICE THAT WILL PRODUCE AEROSOLIZED DRUG PARTICLES < 1 MM IN SIZE, WHICH IS THE OPTIMUM PARTICLE SIZE TO ALLOW EVEN DRUG DISTRIBUTION TO THE DISTAL LUNGS. WE WILL THEN OPTIMIZE THE SURGICAL PROCEDURE FOR IMPLANTATION OF THE INTRATRACHEAL DEVICE IN THE TRACHEA OF THE RAT MODEL, QUANTIFY PARTICLE DEPOSITION IN THE LUNG IN SINGLE AND MULTIPLE DOSE STUDIES, AND EVALUATE BIOCOMPATIBILITY OF THE DEVICE. IMPLANTABLE CATHETERS ARE COMMONLY USED FOR DMPK/TOX TESTING OF ORAL AND INTRAVENOUS DRUGS, BUT A TECHNOLOGY FOR AN IMPLANTABLE SYSTEM FOR INHALED DOSING IS NOT YET AVAILABLE. UPON COMPLETION OF PHASE I, WE WILL HAVE A WORKING PROTOTYPE AND SURGICAL IMPLANTATION METHODS FOR AN INTRATRACHEAL DEVICE THAT DEMONSTRATES EFFICIENT PARTICLE DISTRIBUTION IN THE LUNGS WHEN ADMINISTERED VIA AIRWAY USING SINGLE OR MULTIPLE DOSING STRATEGIES. THIS WILL PROVIDE THE FOUNDATION FOR PHASE II STUDIES, IN WHICH WE WILL EVALUATE COSTS, CONDUCT COMPARATIVE DMPK/TOX STUDIES WITH EXISTING INHALATION DOSING METHODS, AND DEMONSTRATE UTILITY IN DISEASE MODELS IN ORDER TO DEFINE SPECIFIC VIABLE MARKET SECTORS. THE INTEGRATION OF A NEW TOOL FOR PRECLINICAL DEVELOPMENT OF RESPIRATORY DRUGS WILL GREATLY IMPROVE THE EARLY STAGE DRUG DEVELOPMENT PROCESS FOR RESPIRATORY DRUGS AND HELP ADVANCE THERAPEUTICS TOWARDS FDA APPROVAL.
$0
2/15/23
Not listed
DEVELOPMENT OF AN INTRATRACHEAL DEVICE TO AUTOMATE AIRWAY DRUG DELIVERY IN ANIMAL MODELS - PROJECT SUMMARY / ABSTRACT THE RATE OF FDA APPROVAL FOR RESPIRATORY DRUGS IS ONLY 3%, MUCH LOWER THAN DRUGS DEVELOPED FOR OTHER KEY THERAPEUTIC AREAS. THE LOWER SUCCESS RATE FOR RESPIRATORY DRUGS CAN BE ATTRIBUTED TO THE LACK OF INNOVATION FOR DEVELOPING INHALED THERAPEUTICS, ESPECIALLY TOOLS NEEDED FOR EARLY DRUG DEVELOPMENT PHASES. THE EARLY ASSESSMENT OF A DRUG'S METABOLISM, PHARMACOKINETICS, AND TOXICOLOGY (DMPK/TOX) ARE EXTREMELY CRITICAL. PRECLINICAL ANIMAL STUDIES REDUCE THE TIME AND COSTS EXPENDED WITH THE DEVELOPMENT OF NEW DRUGS, THUS INCREASING THE OVERALL SUCCESS OF BRINGING NEW THERAPIES TO MARKET. HOWEVER, FOR ANIMAL MODELS OF LUNG DISEASES, CURRENT METHODS FOR AIRWAY DOSING HAVE MAJOR LIMITATIONS THAT GREATLY AFFECT THE DATA QUALITY, RELIABILITY AND FEASIBILITY OF DMPK/TOX STUDIES. TO ADDRESS THESE LIMITATIONS, OUR PROPOSED PROJECT WILL DEVELOP A NEW TOOL FOR USE DURING THE PRECLINICAL STAGES OF DRUG DEVELOPMENT OF INHALED THERAPEUTICS. WE WILL DESIGN AND ASSEMBLE A WORKING PROTOTYPE OF A MINIATURIZED INTRATRACHEAL DEVICE THAT WILL PRODUCE AEROSOLIZED DRUG PARTICLES < 1 MM IN SIZE, WHICH IS THE OPTIMUM PARTICLE SIZE TO ALLOW EVEN DRUG DISTRIBUTION TO THE DISTAL LUNGS. WE WILL THEN OPTIMIZE THE SURGICAL PROCEDURE FOR IMPLANTATION OF THE INTRATRACHEAL DEVICE IN THE TRACHEA OF THE RAT MODEL, QUANTIFY PARTICLE DEPOSITION IN THE LUNG IN SINGLE AND MULTIPLE DOSE STUDIES, AND EVALUATE BIOCOMPATIBILITY OF THE DEVICE. IMPLANTABLE CATHETERS ARE COMMONLY USED FOR DMPK/TOX TESTING OF ORAL AND INTRAVENOUS DRUGS, BUT A TECHNOLOGY FOR AN IMPLANTABLE SYSTEM FOR INHALED DOSING IS NOT YET AVAILABLE. UPON COMPLETION OF PHASE I, WE WILL HAVE A WORKING PROTOTYPE AND SURGICAL IMPLANTATION METHODS FOR AN INTRATRACHEAL DEVICE THAT DEMONSTRATES EFFICIENT PARTICLE DISTRIBUTION IN THE LUNGS WHEN ADMINISTERED VIA AIRWAY USING SINGLE OR MULTIPLE DOSING STRATEGIES. THIS WILL PROVIDE THE FOUNDATION FOR PHASE II STUDIES, IN WHICH WE WILL EVALUATE COSTS, CONDUCT COMPARATIVE DMPK/TOX STUDIES WITH EXISTING INHALATION DOSING METHODS, AND DEMONSTRATE UTILITY IN DISEASE MODELS IN ORDER TO DEFINE SPECIFIC VIABLE MARKET SECTORS. THE INTEGRATION OF A NEW TOOL FOR PRECLINICAL DEVELOPMENT OF RESPIRATORY DRUGS WILL GREATLY IMPROVE THE EARLY STAGE DRUG DEVELOPMENT PROCESS FOR RESPIRATORY DRUGS AND HELP ADVANCE THERAPEUTICS TOWARDS FDA APPROVAL.
$0
2/15/23
Not listed
DEVELOPMENT OF AN INTRATRACHEAL DEVICE TO AUTOMATE AIRWAY DRUG DELIVERY IN ANIMAL MODELS - PROJECT SUMMARY / ABSTRACT THE RATE OF FDA APPROVAL FOR RESPIRATORY DRUGS IS ONLY 3%, MUCH LOWER THAN DRUGS DEVELOPED FOR OTHER KEY THERAPEUTIC AREAS. THE LOWER SUCCESS RATE FOR RESPIRATORY DRUGS CAN BE ATTRIBUTED TO THE LACK OF INNOVATION FOR DEVELOPING INHALED THERAPEUTICS, ESPECIALLY TOOLS NEEDED FOR EARLY DRUG DEVELOPMENT PHASES. THE EARLY ASSESSMENT OF A DRUG'S METABOLISM, PHARMACOKINETICS, AND TOXICOLOGY (DMPK/TOX) ARE EXTREMELY CRITICAL. PRECLINICAL ANIMAL STUDIES REDUCE THE TIME AND COSTS EXPENDED WITH THE DEVELOPMENT OF NEW DRUGS, THUS INCREASING THE OVERALL SUCCESS OF BRINGING NEW THERAPIES TO MARKET. HOWEVER, FOR ANIMAL MODELS OF LUNG DISEASES, CURRENT METHODS FOR AIRWAY DOSING HAVE MAJOR LIMITATIONS THAT GREATLY AFFECT THE DATA QUALITY, RELIABILITY AND FEASIBILITY OF DMPK/TOX STUDIES. TO ADDRESS THESE LIMITATIONS, OUR PROPOSED PROJECT WILL DEVELOP A NEW TOOL FOR USE DURING THE PRECLINICAL STAGES OF DRUG DEVELOPMENT OF INHALED THERAPEUTICS. WE WILL DESIGN AND ASSEMBLE A WORKING PROTOTYPE OF A MINIATURIZED INTRATRACHEAL DEVICE THAT WILL PRODUCE AEROSOLIZED DRUG PARTICLES < 1 MM IN SIZE, WHICH IS THE OPTIMUM PARTICLE SIZE TO ALLOW EVEN DRUG DISTRIBUTION TO THE DISTAL LUNGS. WE WILL THEN OPTIMIZE THE SURGICAL PROCEDURE FOR IMPLANTATION OF THE INTRATRACHEAL DEVICE IN THE TRACHEA OF THE RAT MODEL, QUANTIFY PARTICLE DEPOSITION IN THE LUNG IN SINGLE AND MULTIPLE DOSE STUDIES, AND EVALUATE BIOCOMPATIBILITY OF THE DEVICE. IMPLANTABLE CATHETERS ARE COMMONLY USED FOR DMPK/TOX TESTING OF ORAL AND INTRAVENOUS DRUGS, BUT A TECHNOLOGY FOR AN IMPLANTABLE SYSTEM FOR INHALED DOSING IS NOT YET AVAILABLE. UPON COMPLETION OF PHASE I, WE WILL HAVE A WORKING PROTOTYPE AND SURGICAL IMPLANTATION METHODS FOR AN INTRATRACHEAL DEVICE THAT DEMONSTRATES EFFICIENT PARTICLE DISTRIBUTION IN THE LUNGS WHEN ADMINISTERED VIA AIRWAY USING SINGLE OR MULTIPLE DOSING STRATEGIES. THIS WILL PROVIDE THE FOUNDATION FOR PHASE II STUDIES, IN WHICH WE WILL EVALUATE COSTS, CONDUCT COMPARATIVE DMPK/TOX STUDIES WITH EXISTING INHALATION DOSING METHODS, AND DEMONSTRATE UTILITY IN DISEASE MODELS IN ORDER TO DEFINE SPECIFIC VIABLE MARKET SECTORS. THE INTEGRATION OF A NEW TOOL FOR PRECLINICAL DEVELOPMENT OF RESPIRATORY DRUGS WILL GREATLY IMPROVE THE EARLY STAGE DRUG DEVELOPMENT PROCESS FOR RESPIRATORY DRUGS AND HELP ADVANCE THERAPEUTICS TOWARDS FDA APPROVAL.
$0
8/9/21
Not listed
DEVELOPMENT OF AN INTRATRACHEAL DEVICE TO AUTOMATE AIRWAY DRUG DELIVERY IN ANIMAL MODELS - PROJECT SUMMARY / ABSTRACT THE RATE OF FDA APPROVAL FOR RESPIRATORY DRUGS IS ONLY 3%, MUCH LOWER THAN DRUGS DEVELOPED FOR OTHER KEY THERAPEUTIC AREAS. THE LOWER SUCCESS RATE FOR RESPIRATORY DRUGS CAN BE ATTRIBUTED TO THE LACK OF INNOVATION FOR DEVELOPING INHALED THERAPEUTICS, ESPECIALLY TOOLS NEEDED FOR EARLY DRUG DEVELOPMENT PHASES. THE EARLY ASSESSMENT OF A DRUG'S METABOLISM, PHARMACOKINETICS, AND TOXICOLOGY (DMPK/TOX) ARE EXTREMELY CRITICAL. PRECLINICAL ANIMAL STUDIES REDUCE THE TIME AND COSTS EXPENDED WITH THE DEVELOPMENT OF NEW DRUGS, THUS INCREASING THE OVERALL SUCCESS OF BRINGING NEW THERAPIES TO MARKET. HOWEVER, FOR ANIMAL MODELS OF LUNG DISEASES, CURRENT METHODS FOR AIRWAY DOSING HAVE MAJOR LIMITATIONS THAT GREATLY AFFECT THE DATA QUALITY, RELIABILITY AND FEASIBILITY OF DMPK/TOX STUDIES. TO ADDRESS THESE LIMITATIONS, OUR PROPOSED PROJECT WILL DEVELOP A NEW TOOL FOR USE DURING THE PRECLINICAL STAGES OF DRUG DEVELOPMENT OF INHALED THERAPEUTICS. WE WILL DESIGN AND ASSEMBLE A WORKING PROTOTYPE OF A MINIATURIZED INTRATRACHEAL DEVICE THAT WILL PRODUCE AEROSOLIZED DRUG PARTICLES < 1 MM IN SIZE, WHICH IS THE OPTIMUM PARTICLE SIZE TO ALLOW EVEN DRUG DISTRIBUTION TO THE DISTAL LUNGS. WE WILL THEN OPTIMIZE THE SURGICAL PROCEDURE FOR IMPLANTATION OF THE INTRATRACHEAL DEVICE IN THE TRACHEA OF THE RAT MODEL, QUANTIFY PARTICLE DEPOSITION IN THE LUNG IN SINGLE AND MULTIPLE DOSE STUDIES, AND EVALUATE BIOCOMPATIBILITY OF THE DEVICE. IMPLANTABLE CATHETERS ARE COMMONLY USED FOR DMPK/TOX TESTING OF ORAL AND INTRAVENOUS DRUGS, BUT A TECHNOLOGY FOR AN IMPLANTABLE SYSTEM FOR INHALED DOSING IS NOT YET AVAILABLE. UPON COMPLETION OF PHASE I, WE WILL HAVE A WORKING PROTOTYPE AND SURGICAL IMPLANTATION METHODS FOR AN INTRATRACHEAL DEVICE THAT DEMONSTRATES EFFICIENT PARTICLE DISTRIBUTION IN THE LUNGS WHEN ADMINISTERED VIA AIRWAY USING SINGLE OR MULTIPLE DOSING STRATEGIES. THIS WILL PROVIDE THE FOUNDATION FOR PHASE II STUDIES, IN WHICH WE WILL EVALUATE COSTS, CONDUCT COMPARATIVE DMPK/TOX STUDIES WITH EXISTING INHALATION DOSING METHODS, AND DEMONSTRATE UTILITY IN DISEASE MODELS IN ORDER TO DEFINE SPECIFIC VIABLE MARKET SECTORS. THE INTEGRATION OF A NEW TOOL FOR PRECLINICAL DEVELOPMENT OF RESPIRATORY DRUGS WILL GREATLY IMPROVE THE EARLY STAGE DRUG DEVELOPMENT PROCESS FOR RESPIRATORY DRUGS AND HELP ADVANCE THERAPEUTICS TOWARDS FDA APPROVAL.
$0
8/9/21
Not listed
DEVELOPMENT OF AN INTRATRACHEAL DEVICE TO AUTOMATE AIRWAY DRUG DELIVERY IN ANIMAL MODELS - PROJECT SUMMARY / ABSTRACT THE RATE OF FDA APPROVAL FOR RESPIRATORY DRUGS IS ONLY 3%, MUCH LOWER THAN DRUGS DEVELOPED FOR OTHER KEY THERAPEUTIC AREAS. THE LOWER SUCCESS RATE FOR RESPIRATORY DRUGS CAN BE ATTRIBUTED TO THE LACK OF INNOVATION FOR DEVELOPING INHALED THERAPEUTICS, ESPECIALLY TOOLS NEEDED FOR EARLY DRUG DEVELOPMENT PHASES. THE EARLY ASSESSMENT OF A DRUG'S METABOLISM, PHARMACOKINETICS, AND TOXICOLOGY (DMPK/TOX) ARE EXTREMELY CRITICAL. PRECLINICAL ANIMAL STUDIES REDUCE THE TIME AND COSTS EXPENDED WITH THE DEVELOPMENT OF NEW DRUGS, THUS INCREASING THE OVERALL SUCCESS OF BRINGING NEW THERAPIES TO MARKET. HOWEVER, FOR ANIMAL MODELS OF LUNG DISEASES, CURRENT METHODS FOR AIRWAY DOSING HAVE MAJOR LIMITATIONS THAT GREATLY AFFECT THE DATA QUALITY, RELIABILITY AND FEASIBILITY OF DMPK/TOX STUDIES. TO ADDRESS THESE LIMITATIONS, OUR PROPOSED PROJECT WILL DEVELOP A NEW TOOL FOR USE DURING THE PRECLINICAL STAGES OF DRUG DEVELOPMENT OF INHALED THERAPEUTICS. WE WILL DESIGN AND ASSEMBLE A WORKING PROTOTYPE OF A MINIATURIZED INTRATRACHEAL DEVICE THAT WILL PRODUCE AEROSOLIZED DRUG PARTICLES < 1 MM IN SIZE, WHICH IS THE OPTIMUM PARTICLE SIZE TO ALLOW EVEN DRUG DISTRIBUTION TO THE DISTAL LUNGS. WE WILL THEN OPTIMIZE THE SURGICAL PROCEDURE FOR IMPLANTATION OF THE INTRATRACHEAL DEVICE IN THE TRACHEA OF THE RAT MODEL, QUANTIFY PARTICLE DEPOSITION IN THE LUNG IN SINGLE AND MULTIPLE DOSE STUDIES, AND EVALUATE BIOCOMPATIBILITY OF THE DEVICE. IMPLANTABLE CATHETERS ARE COMMONLY USED FOR DMPK/TOX TESTING OF ORAL AND INTRAVENOUS DRUGS, BUT A TECHNOLOGY FOR AN IMPLANTABLE SYSTEM FOR INHALED DOSING IS NOT YET AVAILABLE. UPON COMPLETION OF PHASE I, WE WILL HAVE A WORKING PROTOTYPE AND SURGICAL IMPLANTATION METHODS FOR AN INTRATRACHEAL DEVICE THAT DEMONSTRATES EFFICIENT PARTICLE DISTRIBUTION IN THE LUNGS WHEN ADMINISTERED VIA AIRWAY USING SINGLE OR MULTIPLE DOSING STRATEGIES. THIS WILL PROVIDE THE FOUNDATION FOR PHASE II STUDIES, IN WHICH WE WILL EVALUATE COSTS, CONDUCT COMPARATIVE DMPK/TOX STUDIES WITH EXISTING INHALATION DOSING METHODS, AND DEMONSTRATE UTILITY IN DISEASE MODELS IN ORDER TO DEFINE SPECIFIC VIABLE MARKET SECTORS. THE INTEGRATION OF A NEW TOOL FOR PRECLINICAL DEVELOPMENT OF RESPIRATORY DRUGS WILL GREATLY IMPROVE THE EARLY STAGE DRUG DEVELOPMENT PROCESS FOR RESPIRATORY DRUGS AND HELP ADVANCE THERAPEUTICS TOWARDS FDA APPROVAL.
$0
10/17/20